Bottom line
A research-market growth-hormone-axis combination pairing sermorelin, a GHRH(1-29) analog with historical FDA-approved finished-drug products, and ipamorelin, an investigational growth-hormone secretagogue. Each component has separate evidence, but no published randomized trial was identified for the specific combination. Evidence for either component alone cannot establish the combination's efficacy, safety, dose ratio, or stability.
No established or recommended human dose.
Name and formulation variability
| Observed source/date | Claimed components | Claimed amounts | Verification limits |
|---|---|---|---|
| RCDbio (accessed 2026) | Sermorelin, Ipamorelin | Vendor-specific | Vendor marketing page; identity, purity, and sterility were not independently verified |
| Peptigrity (accessed 2026) | Sermorelin, Ipamorelin | Vendor-specific | Vendor testing page; not evidence of clinical equivalence or combination efficacy |
Also known as: Sermorelin/Ipamorelin and GHRH(1-29) + Ipamorelin. Informal labels such as "clean GH stack" are marketing language, not a validated clinical characterization.
Component evidence
| Component | Separate evidence | Evidence for combination | Compatibility/stability evidence |
|---|---|---|---|
| Sermorelin | Geref diagnostic (NDA 19-863) was approved in 1990; the pediatric-treatment product (NDA 20-443) was approved in 1997. A 1996 open-label study enrolled 110 children and analyzed efficacy in 86 after one year of GHRH(1-29) treatment | No published RCT of the specific combination | No published co-formulation stability study identified |
| Ipamorelin | Raun 1998 characterized selectivity in rat and swine models; Gobburu 1999 studied IV PK/PD in five cohorts of eight healthy men; Beck 2014 was a negative randomized phase-2 postoperative-ileus study (117 enrolled) | No published RCT with sermorelin | No published co-formulation stability study identified |
Raun et al. reported that ipamorelin did not increase ACTH or cortisol beyond the GHRH response in conscious swine, unlike GHRP-2 and GHRP-6 in that animal model. That preclinical comparison does not establish an off-target advantage in humans or validate the sermorelin-ipamorelin combination. Gobburu et al. characterized ipamorelin PK/GH response in healthy men, while Beck et al. found no significant benefit on the primary or secondary efficacy endpoints in postoperative ileus.
Combination-specific studies
No published human RCT was identified that tests sermorelin + ipamorelin as a specific combination.
Safety and interaction uncertainties
Historical pharmaceutical-grade sermorelin data cannot establish the safety or quality of current research-market material
Ipamorelin's selectivity claim comes primarily from animal pharmacology and should not be generalized to combination safety in humans
No combination-specific safety data
No published compatibility, sterility, or co-formulation stability data were identified
Regulatory and product-quality notes
Geref diagnostic (NDA 19-863) was approved December 28, 1990; the pediatric treatment presentation (NDA 20-443) was approved September 26, 1997
The sponsor reported discontinuation in 2008, and FDA withdrew both NDA approvals effective June 18, 2009. FDA later determined that the products were not withdrawn for reasons of safety or effectiveness
Neither component is currently FDA-approved for any indication
The 2026 WADA List explicitly names sermorelin among GHRH analogues and ipamorelin among growth-hormone secretagogues and their mimetics in section S2.2.4; both are prohibited at all times
Research-grade material is not pharmaceutical GMP
Evidence gaps
No combination study (human or animal)
No dose-ratio optimisation
No co-stability data
Research-grade Sermorelin purity/consistency not equivalent to former pharmaceutical product
Sources
FDA. Determination that Geref products were not withdrawn for reasons of safety or effectiveness. 78 FR 14095 (March 4, 2013). Includes the 1990 and 1997 approvals, 2008 sponsor notices, and June 18, 2009 effective withdrawal. https://www.govinfo.gov/content/pkg/FR-2013-03-04/pdf/2013-04827.pdf
FDA Orphan Drug Designations and Approvals. Sermorelin acetate (Geref), pediatric treatment marketing approval September 26, 1997. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687&sid=g1_mnxuuiosj4sj6y
Thorner M, et al.; Geref International Study Group. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. J Clin Endocrinol Metab. 1996;81(3):1189-1196. PMID: 8772599. https://pubmed.ncbi.nlm.nih.gov/8772599/
Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822. https://pubmed.ncbi.nlm.nih.gov/9849822/
Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416. PMID: 10496658. https://pubmed.ncbi.nlm.nih.gov/10496658/
Beck DE, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-1534. PMID: 25331030. https://pubmed.ncbi.nlm.nih.gov/25331030/
PubChem. Sermorelin (CID 16132413). https://pubchem.ncbi.nlm.nih.gov/compound/16132413
RCDbio. Sermorelin + Ipamorelin Blend. Vendor page used only to document a marketed blend name; claims were not independently verified. https://rcdbio.co/product/sermorelin-ipamorelin-blend-peptide/
Peptigrity. Sermorelin + Ipamorelin testing. Vendor page used only to document formulation variability; claims were not independently verified. https://peptigrity.com/peptides/sermorelin-ipamorelin
World Anti-Doping Agency. 2026 Prohibited List, section S2.2.4. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf